Evidence map›Paper›PMID 38816815›Full record

ArticleChinese medicine2024

A simplified herbal decoction attenuates myocardial infarction by regulating macrophage metabolic reprogramming and phenotypic differentiation via modulation of the HIF-1α/PDK1 axis.

Zhi-Jun Lin, Xin Dong, Huan He, Jia-Lin Jiang, Zhuo-Ji Guan, Xuan Li, Lu Lu, Huan Li, Yu-Sheng Huang, Shao-Xiang Xian and 4 more

Abstract read
In one paragraph

Article in Chinese medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Zhi-Jun LinState Key Laboratory of Traditional Chinese Medicine Syndrome,The First Affiliated Hospital of Guangzhou University of Chinese Medicine, No. 12 Jichang Road, Baiyun District, Guangzhou, 510405, People's Republic of China.ORCID http://orcid.org/0000-0003-2425-9298
Xin DongState Key Laboratory of Traditional Chinese Medicine Syndrome,The First Affiliated Hospital of Guangzhou University of Chinese Medicine, No. 12 Jichang Road, Baiyun District, Guangzhou, 510405, People's Republic of China.
Huan HeState Key Laboratory of Traditional Chinese Medicine Syndrome,The First Affiliated Hospital of Guangzhou University of Chinese Medicine, No. 12 Jichang Road, Baiyun District, Guangzhou, 510405, People's Republic of China.
Jia-Lin JiangState Key Laboratory of Traditional Chinese Medicine Syndrome,The First Affiliated Hospital of Guangzhou University of Chinese Medicine, No. 12 Jichang Road, Baiyun District, Guangzhou, 510405, People's Republic of China.
Zhuo-Ji GuanState Key Laboratory of Traditional Chinese Medicine Syndrome,The First Affiliated Hospital of Guangzhou University of Chinese Medicine, No. 12 Jichang Road, Baiyun District, Guangzhou, 510405, People's Republic of China.
Xuan LiState Key Laboratory of Traditional Chinese Medicine Syndrome,The First Affiliated Hospital of Guangzhou University of Chinese Medicine, No. 12 Jichang Road, Baiyun District, Guangzhou, 510405, People's Republic of China.
Lu LuState Key Laboratory of Traditional Chinese Medicine Syndrome,The First Affiliated Hospital of Guangzhou University of Chinese Medicine, No. 12 Jichang Road, Baiyun District, Guangzhou, 510405, People's Republic of China.
Huan LiState Key Laboratory of Traditional Chinese Medicine Syndrome,The First Affiliated Hospital of Guangzhou University of Chinese Medicine, No. 12 Jichang Road, Baiyun District, Guangzhou, 510405, People's Republic of China.
Yu-Sheng HuangState Key Laboratory of Traditional Chinese Medicine Syndrome,The First Affiliated Hospital of Guangzhou University of Chinese Medicine, No. 12 Jichang Road, Baiyun District, Guangzhou, 510405, People's Republic of China.
Shao-Xiang XianState Key Laboratory of Traditional Chinese Medicine Syndrome,The First Affiliated Hospital of Guangzhou University of Chinese Medicine, No. 12 Jichang Road, Baiyun District, Guangzhou, 510405, People's Republic of China.
Zhong-Qi YangState Key Laboratory of Traditional Chinese Medicine Syndrome,The First Affiliated Hospital of Guangzhou University of Chinese Medicine, No. 12 Jichang Road, Baiyun District, Guangzhou, 510405, People's Republic of China.
Zi-Xin ChenState Key Laboratory of Traditional Chinese Medicine Syndrome,The First Affiliated Hospital of Guangzhou University of Chinese Medicine, No. 12 Jichang Road, Baiyun District, Guangzhou, 510405, People's Republic of China. zxchen@gzucm.edu.cn.
Hong-Cheng FangLingnan Medical Research Center, Guangdong Clinical Researh Academy of Chinese Medicine, No. 12 Jichang Road, Baiyun District, Guangzhou, 510405, People's Republic of China. kl520mm@126.com.
Ling-Jun WangState Key Laboratory of Traditional Chinese Medicine Syndrome,The First Affiliated Hospital of Guangzhou University of Chinese Medicine, No. 12 Jichang Road, Baiyun District, Guangzhou, 510405, People's Republic of China. smu868@163.com.

Funding

Guangdong Provincial Department of Science and Technology 2019A1515110374National Natural Science Foundation of China 82004293
6 · The paper itself

Abstract

backgroundMyocardial infarction (MI) poses a global public health challenge, often associated with elevated mortality rates and a grim prognosis. A crucial aspect of the inflammatory injury and healing process post-MI involves the dynamic differentiation of macrophages. A promising strategy to alleviate myocardial damage after MI is by modulating the inflammatory response and orchestrating the shift from pro-inflammatory (M1) to anti-inflammatory (M2) macrophages, aiming to achieve a reduced M1/M2 ratio. Nuanxinkang (NXK), a simplified herbal decoction, has demonstrated noteworthy cardioprotective, inflammation-regulating, and myocardial energy metabolism-regulating properties.

methodsIn this study, we constructed an MI model by ligating coronary arteries to investigate the efficacy of NXK in improving ventricular remodeling and cardiac function. Mice were administered NXK (1.65 g/kg/d) or an equivalent volume of regular saline via gavage for 28 consecutive days, commencing the day after surgery. Then, we conducted echocardiography to assess the cardiac function, Masson staining to illustrate the extent of myocardial fibrosis, TUNEL staining to reveal myocardial apoptosis, and flow cytometry to analyze the polarization of M1 and M2 macrophages in the hearts. Besides, a lipopolysaccharide (LPS)-induced pro-inflammatory macrophage (M1) polarization model was implemented in RAW264.7 cells to elucidate the underlying mechanism of NXK in regulating macrophage polarization. RAW264.7 cells were pre-treated with or without NXK-containing serum. Oxidative stress was detected by MitoSox staining, followed by Seahorse energy metabolism assay to evaluate alterations in mitochondrial metabolic patterns and ATP production. Both In vivo and in vitro, HIF-1α and PDK1 were detected by fluorescent quantitative PCR and Western blotting.

resultsIn vivo, MI mice exhibited a decline in cardiac function, adverse ventricular remodeling, and an increase in glycolysis, coupled with M1-dominant polarization mediated by the HIF-1α/PDK1 axis. Notably, robust responses were evident with high-dose NXK treatment (1.65 g/kg/day), leading to a significant enhancement in cardiac function, inhibition of cardiac remodeling, and partial suppression of macrophage glycolysis and the inflammatory phenotype in MI mice. This effect was achieved through the modulation of the HIF-1α/PDK1 axis. In vitro, elevated levels of mitochondrial ROS production and glycolysis were observed in LPS-induced macrophages. Conversely, treatment with NXK notably reduced the oxidative stress damage induced by LPS and enhanced oxidative phosphorylation (OXPHOS). Furthermore, NXK demonstrated the ability to modify the energy metabolism and inflammatory characteristics of macrophages by modulating the HIF-1α/PDK1 axis. The influence of NXK on this axis was partially counteracted by the HIF-1α agonist DMOG. And NXK downregulated PDK1 expression, curtailed glycolysis, and reversed LPS-induced M1 polarization in macrophages, similar to the PDK1 inhibitor DCA.

conclusionIn conclusion, NXK protects against MI-induced cardiac remodeling by inducing metabolic reprogramming and phenotypic differentiation of macrophages, achieved through the modulation of the HIF-1α/PDK1 axis. This provides a novel and promising strategy for the treatment of MI.

Indexed as

Energy metabolismMacrophages polarizationMyocardial Infarction (MI)Nuanxinkang (NXK)

Identifiers

PMID38816815
PMCPMC11140944

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.